<DOC>
	<DOCNO>NCT02746237</DOCNO>
	<brief_summary>Safety , tolerability , pharmacokinetics ( PK ) , cardiac conduction food effect study single multiple ascend dos KAR5585 healthy adult .</brief_summary>
	<brief_title>Single Multiple Ascending Doses Clinical Pharmacology Study With KAR5585</brief_title>
	<detailed_description>The purpose study explore safety , tolerability , pharmacokinetics ( PK ) , cardiac conduction effect single multiple ascend dos KAR5585 healthy adult . Food effect also evaluate single-dose administration .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Subject able read , write , comprehend English sufficient level understand studyrelated material Subject able provide write informed consent comply study requirement restriction Subject male female age 18 65 year , inclusive , time informed consent Subject good health determine PI base detailed medical history , physical examination , vital sign , clinical laboratory test , ECGs , predose evaluation Subject agree use medically acceptable form birth control CRU admission least 30 day ( female subject ) 90 day ( male subject ) last dose study drug . Males also donate sperm CRU admission least 90 day last dose study drug . If subject sexually active becomes active study participation , subject agree partner use medically accept form contraception time specify . Medically acceptable form contraception : FDAapproved female hormonal contraceptive use consistently 2 cycle Screening , include oral contraceptive , intrauterine device ( IUD ) , medroxyprogesterone acetate injection ( Depo Provera® ) , hormonal implant ( Norplant® , Implanon® , Nexplanon® ) , vaginal ring ( NuvaRing® ) Male condom plus spermicide Male condom plus contraceptive sponge , foam , jelly Female condom plus spermicide Diaphragm spermicide plus male condom Cervical cap spermicide plus male condom Surgical sterilization subject partner ( vasectomy male , hysterectomy bilateral oophorectomy female ) Abstinence If female , subject agree serum pregnancy test ( [ β hCG ] beta human chorionic gonadotropin ) perform Screening , Day 2 ( CRU admission ) , last study visit negative test result Screening CRU admission require consider study participation Subject body mass index ( BMI ) 20 35 kg/m2 , inclusive , body weight &lt; 120 kg Screening Subject currently use tobacco nicotinecontaining product use product within 6 month CRU admission Subject history current evidence clinically significant cardiac , endocrinologic , hematologic , hepatobiliary , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine PI Subject history cancer within 5 year CRU admission ( exclude nonmelanoma skin cancer ) Subject history autonomic dysfunction ( eg , history repeat dizziness , fainting , symptomatic orthostatic hypotension ) Subject history risk factor torsades de pointes , include unexplained syncope , know long QT syndrome , heart failure , myocardial infarction , angina , OR clinically significant abnormal laboratory assessment include hypokalemia , hypomagnesemia , hypercalcemia OR family history long QT syndrome Brugada syndrome Subject 1 clinically significant abnormal laboratory test value ( determine PI ) Subject uninterpretable abnormal screening ECG indicate second thirddegree atrioventricular block , 1 following : QRS interval ( ventricular depolarization ) &gt; 110 msec ; PR interval ( atrioventricular conduction ) &gt; 220 msec , QTc ( correct QT interval ) ≥ 450 msec ( male ) ≥ 470 msec ( female ) rhythm sinus rhythm interpret PI qualify designee clinically significant Subject rest heart rate ( HR ) &lt; 40 beats/min &gt; 90 beats/min Screening CRU admission Subject sustain supine systolic blood pressure ( BP ) &gt; 155 &lt; 90 mm Hg supine diastolic BP &gt; 95 &lt; 50 mm Hg Screening upon CRU admission . Blood pressure supine position may retested 'sustained ' define parameter ( either systolic diastolic BP ) outside state limit assessment . Subject participate another clinical trial treatment investigational agent within 30 day 5 halflives , whichever longer , CRU admission Subject history alcohol drug abuse dependence within 12 month CRU admission , determine PI Subject clinically significant infection within 3 month CRU admission , determine PI Subject condition , opinion PI , would make subject unsuitable enrollment could interfere subject 's participation completion study Subject positive urine screen prohibit drug ( cocaine , cannabinoids , nicotine [ urine cotinine detection mechanism nicotine ] , opiates , barbiturate , amphetamine , benzodiazepine ) positive urine test alcohol Subject positive blood screen human immunodeficiency virus , hepatitis B surface antigen , hepatitis C virus antibody Screening Visit Subject know suspected hypersensitivity idiosyncratic reaction cellulose use placebo use study Subject donate blood blood product within 3 month Screening plan donate blood within 3 month study completion Subject consume excessive amount caffeine daily , define &gt; 4 cup coffee equivalent per day . Subjects abstain caffeine consumption 48 hour dose confine CRU . Subject consume consume concomitant therapy ; prescription overthecounter ( OTC ) medication ; nutritional , herbal , vitamin supplement contraceptive ( eg , oral , systemic ) ibuprofen ( need , maximum 2.4 g/day ) 14 day 5 halflives ( whichever longer ) dose confine CRU For Part 2 : Subject consume food , juice , beverage , medication ( prescription nonprescription ) contain acetaminophen , alcohol , avocado , banana , caffeine , eggplant , kiwi fruit , nut ( hickory nut , pecan , walnut ) , pineapple , plum , tomato product within 48 hour CRU admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Serotonin</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>